On 26 January, AC Immune, a clinical-stage biopharmaceutical company focused on neurodegenerative diseases, announced the first interim data from its Phase Ib/IIa ABATE trial evaluating ACI-24.060 in prodromal Alzheimer’s disease (AD). The ABATE trial is a Phase Ib/II, multicenter, adaptive, double-blind, randomised and placebo-controlled study evaluating the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-24.060, which is an amyloid-beta (Aß) vaccine.
All participants in the trial must have brain amyloid beta pathology confirmed by a positron emission tomography (PET) scan. Early results from the first cohort of people with AD showed that low dose of ACI-24.060 could elicit an anti-Aß antibody response (as soon as week 6). Additionally, the drug was generally well tolerated with no safety concerns observed. As a result, dosing with higher dose in people with AD has begun and the trial will start to include people with Down syndrome (DS) for the second part of the study. Further safety and immunogenicity findings from the ABATE study are expected in the second half of 2023 and initial data on amyloid plaque reduction measured via PET imaging are anticipated in 2024.
